Atopic dermatitis: experimentalmodels for study of pathogenesis and development of new methods of treatment



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atopic dermatitis (AD) is characterized by allergic skin inflammation. A hallmark of AD is dry itchy skin due, at
least in part, to defects in skin genes that are important for maintaining barrier function. The pathogenesis of AD
remains incompletely understood. A number of mouse models of AD have been developed. This review discusses
these models and emphasizes the role of mechanical skin injury and skin barrier dysfunction in eliciting allergic
skin inflammation. Also, we describe various approaches to the treatment of atopic dermatitis, the latest of which
is the introduction of siRN A. Development of drugs based on siRN A using functional peptides is a promising
area of research in allergology.

About the authors

N N Shershakova

Email: nsh18.81@mail.ru

A A Babakhin

O G Elisyutina

M R Khaitov

N N Shershakova

Institute of Immunology

Institute of Immunology

A A Babakhin

Institute of Immunology

Institute of Immunology

O G Elisyutina

Institute of Immunology

Institute of Immunology

M R Khaitov

Institute of Immunology

Institute of Immunology

References

  1. Jin Н., Не R., Oyoshi M., Geha R. Animal models of atopic dermatitis. J. Invest. Dermatol. 2009, v. 129, p. 31-40.
  2. Sanford A.J. Genetic map of cromosome llg, including the atopy locus. Eur. Hum. Genet. 1995, v. 3, p. 188.
  3. Суворова К.Н. Атопический дерматит: иммунопатогенез и стратегия иммунотерапии. Русский мед. журнал. 1998, т. 6, с. 368-367.
  4. Баранов А.А. и соавт. Атопический дерматит и инфекции кожи у детей: диагностика, лечение и профилактика. Пособие для врачей. М., 2004.
  5. Martinez F.D., Holt P.G. Role of microbial burden in a etiology of allergy and asthma. Lancet. 1999, v. 9, p. 354.
  6. Leung D.Y., Boguniewicz M., Howell M.D. et al. New insights into atopic dermatitis. J. Clin. Invest. 2004, v. 113, p. 651-7.
  7. Ярилин A.A. Основы иммунологии: Учебник. М., «Медицина». 1999, с. 125.
  8. Laouini D., Alenius H., Bryce P., Oettgen H., Tsitsikov E., Geha R. S. IL-10 is critical for Th2 responses in a murine model of allergic dermatitis. The Journal of Clinical Investigation. 2003, v. 112, p. 1058-1066.
  9. Kimura M., Tsuruta S., Yoshida X. Correlation of house dust mite-specific lymphocyte proliferation with IL-5 production, eosinophilia, and the severity of symptoms in infants with atopic dermatitis. J. Allergy Clin. Immunol. 1998, v. 101, p. 84-89.
  10. Azuma M., Ritprajak P., Hashiguchi M. Xopical application of siRNA targeting cutaneous dendritic cells in allergic skin disease. Methods in molecular biology. 2010, v. 623, p. 373-380.
  11. Huang C.H., Kuo I.С., Xu H. et al. Mite allergen induces allergic dermatitis with concomitant neurogenic inflammation in mouse. J. Invest. Dermatol. 2003, v. 121, p. 289-293.
  12. Matsumoto K., Mizukoshi K., Oyobikawa M. et al. Establishment of an atopic dermatitis-like skin model in a hairless mouse by repeated elicitation of contact hypersensitivity that enables to conduct functional analyses of the stratum corneum with various non-invasive biophysical instruments. Skin. Res. Xechnol. 2004, v. 10, p. 122-129.
  13. Man M.Q., Hatano Y., Lee S.H. et al. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J. Invest. Dermatol. 2008, v. 128, p. 79-86.
  14. Hatano Y., Man M.Q., Uchida Y. et al. Murine atopic dermatitis responds to peroxisome proliferator-activated receptor a, P/5(but not y), and liver-X-receptor activators. J. Allergy Clin. Immunol. 2010, v. 125, p. 160-169.
  15. Takano H., Yanagisawa R., Inoue K. et al. Di-(2-ethylhexyl) phthalate enhances atopic dermatitis-like skin lesions in mice. Environmental health perspectives. 2006, v. 114, p. 1266-1269.
  16. Laouini D., Kawamoto S., Yalcindag A. et al. Epicutaneous sensitization with superantigen induces allergic skin inflammation. J. Allergy Clin. Immunol. 2003, v. 112, p. 981-987.
  17. Yoshioka T., Hikita I., Matsutani T. et al. DS-Nh as an experimental model of atopic dermatitis induced by Staphylococcus aureus producing staphylococcal enterotoxin C. J. Immunology. 2003, v. 108, v. 562-569.
  18. Hikita I., Yoshioka T., Mizoguchi T. et al. Characterization of dermatitis arising spontaneously in DS-Nh mice maintained under conventional conditions: another possible model for atopic dermatitis. J. Dermatol. Sci. 2002, v. 30, p. 142-153.
  19. Terada M., Tsutsui H., Imai Y. et al. Contribution of IL-18 to atopic-dermatitis-like skin inflammation induced by Staphylococcus aureus product in mice. PNAS. 2006, v. 103, p. 8816-8821.
  20. Chan L.S., Robinson N., Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J. Invest. Dermatol. 2001, v. 117, p. 977-983.
  21. Dillon S.R., Sprecher C., Hammond A. et al. Interleukin-31, a cytokine produced by activated T-cells, induces dermatitis in mice. Nat. Immunol. 2004, v. 5, p. 752-760.
  22. Soumelis V., Reche P.A., Kanzler H. et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 2002, v. 3, p. 673-680.
  23. Yoo J., Omori M., Gyarmati D. et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J. Exp. Med. 2005, v. 202, p. 541-549.
  24. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 regulates both Thl and Th2 responses. Annu. Rev. Immunol. 2001, v. 19, p. 423-474.
  25. Yamanaka K., Tanaka M., Tsutsui H. et al. Skin-specific caspase-1 -transgenic mice show cutaneous apoptosis and pre-endotoxin shock condition with a high serum level of IL-18. J. Immunol. 2000, v. 165, p. 997-1003.
  26. Weih E., Warr G., Yang H., Bravo R. Multifocal defects in immune responses in RelB-deficient mice. J. Immunol. 1997, v. 158, p. 5211-5218.
  27. Barton D., HogenEsch H., Weih F. Mice lacking the transcription factor RelB develop T-cell-dependent skin lesions similar to human atopic dermatitis. Eur. J. Immunol. 2000, v. 30, p. 2323-2332.
  28. Tsukuba T., Okamoto K., Okamoto Y. et al. Association of cathepsin E deficiency with development of atopic dermatitis. J. Biochem (Tokyo). 2003, v. 134, p. 893-902.
  29. Hansson L., Backman A., Ny A. et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J. Invest. Dermatol. 2002, v. 118, p. 444-449.
  30. Nagelkerken L., Verzaal P., Lagerweij T. et al. Development of atopic dermatitis in mice transgenic for human apolipoprotein CI. J. Invest. Dermatol. 2007, v. 128, p. 1165-1172.
  31. Matsuda H., Watanabe N., Geba G.P. et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int. Immunol. 1997, v. 9, p. 461-466.
  32. Matsumoto M., Ra C., Kawamoto K. et al. IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis. J. Immunol. 1999, v. 162, p. 1056-1063.
  33. Kohara Y., Tanabe K., Matsuoka К. et al. A major determinant quantitative-trait locus responsible for atopic dermatitis-like skin lesions in NC/Nga mice is located on Chromosome 9. Immunogenetics. 2001, v. 53, p. 15-21.
  34. Vestergaard C., Yoneyama H., Murai M. et al. Overproduction of Xh2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J. Clin. Invest. 1999, v. 104, p. 1097-1105.
  35. Aioi A., Tonogaito H., Suto H. et al. Impairment of skin barrier function in NC/Nga Xnd mice as a possible model for atopic dermatitis. Br. J. Dermatol. 2001, v. 144, p. 12-18.
  36. Короткий Н.Г., Таганов А.В., Тихомиров А.А. Современная наружная терапия дерматозов (с элементами физиотерапии). 2001, Губернская медицина, Тверь.
  37. Fehervari Z., Sakaguchi S. Peacekeepers of the immune system. Sci. Am. 2006, v. 295 (4), p. 56-63.
  38. Патент на изобретение RU2375375 Авторы: Вижден Жон (FR), Йонулайт Хельмут (DE). Патентообладатель: БИOТECТ AГ(DE).
  39. Moon J.S., Kim H.K., Коо Н.С. et al. The antibacterial and immunostimulative effect of chitosan-oligosaccharides against infection by Staphylococcus aureus isolated from bovine mastitis. Appl. Microbiol. Biotechnol. 2007, v. 75, p. 989-998.
  40. Schlievert P.M. Chitosan malate inhibits growth and exotoxin production of toxic shock syndrome-inducing Staphylococcus aureus strains and group A streptococci. Antimicrob. Agents Chemother. 2007, v. 51 (9), p. 3056-3062.
  41. Большаков И.Н., Насибов С.М., Куклин Е.Ю., Приходько А.А. Использование хитозана и его продуктов при воспалительных заболеваниях желудочно-кишечного тракта. Хитин и хитозан: получение, свойства и применение. М., Изд-во «Наука». 2002, с. 280-301.
  42. Mohapatra S.S., Lockey R.F., Vesely D.X., Gower W.R. Natriuretic peptides and genesis of asthma: an emerging paradigm? J. Allergy Clin. Immunol. 2004, v. 114, p. 520-526.
  43. Wang X., Xu W., Mohapatra S. et al. Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor. Genet. Vaccin. Therapy. 2008, v. 6 (7), p. 15-23.
  44. Хаитов М.Р., Акимов B.C. Интерференция РНК. Усп. совр. биол. 2006, т. 126, с. 242-249.
  45. Uchida T., Kanazawa T., Kawai M., Takashima Y., Okada H. Therapeutic effects on atopic dermatitis by anti-RelA siRNA with functional peptides, TatandAT1002. J. Pharmacol. Exp. Ther. 2011.
  46. Oyoshi M.K., Murphy G.F., Geha R.S. Filaggrin deficient mice exhibit Thl 7-dominanted skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. J. Allergy Clin. Immunol. 2009, v. 124, p. 485-493.

Copyright © Pharmarus Print Media, 1970



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies